Abstract 17β-estradiol (E 2 ) plays a key role in tumorigenesis by enhancing cell survivability and metastasis through its cytoplasmic receptors. Recently, a variant of estrogen receptor alpha, ERα36 has been implicated as a substantial mediator of E 2 's proliferative and antiapoptotic effects through rapid membrane-associated signaling, and cancers previously regarded as hormone-independent due to the absence of traditional receptors, may in fact be susceptible to E 2 . Despite rising from a secondary sex organ and having a clear gender disposition, laryngeal cancer is not uniformly accepted as hormone dependent, even in the face of compelling evidence of E 2 responsiveness . The aim of this study was to further elucidate the role of E 2 in the tumorigenesis of laryngeal cancer, both in vitro and in vivo. ERα36 presence was evaluated in membranes of the laryngeal carcinoma cell line, Hep2, as well as in laryngeal tumor samples. In vitro ERα36 was found to mediate rapid activation of protein kinase C and phospholipase D by E 2 , leading to increased proliferation and protection against chemotherapy-induced apoptosis. Furthermore, in response to E 2 activation of ERα36, an upregulation of angiogenic and metastatic factors was observed. Clinical analysis of laryngeal tumors revealed a similar association between the amount of ERα36 and VEGF and indicated a role in lymph node metastasis. These findings present compelling evidence of ERα36-dependent E 2 signaling in laryngeal cancer. Thus, targeting ERα36 may reduce the deleterious effects of E 2 in laryngeal cancer, ultimately suggesting the importance of antiestrogen therapy or the production of novel drugs that specifically target ERα36.
Introduction
The mechanisms responsible for tumor growth and metastasis are complex and are only partially understood. One of the factors contributing to this process that has major clinical implications for both prognosis and treatment is the presence of hormone and growth factor receptors in cancer cells. 17β-estradiol (E 2 ) traditionally acts as a sex hormone, involved in sexual development and the reproductive systems of males and females, but it has also many other effects both in nonreproductive tissues such as bone and in cancerous tissue. The importance of E 2 in the pathogenesis of breast and prostate cancer is well established [1, 2] . E 2 is known to enhance cell proliferation, survivability, and metastasis [3] [4] [5] . This deleterious effect of E 2 is in fact the target of one of the main treatments in breast cancer, the antiestrogen tamoxifen.
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Classically, the mechanism of E 2 action is mediated through interaction with its receptors, ERα and ERβ, which are found mainly in the nucleus and act as transcription factors [6] . There is increasing evidence that E 2 also acts via plasma membrane receptor(s), which rapidly activate signal transduction pathways, thus enhancing proliferation and attenuating apoptosis [7, 8] . This membrane-mediated mechanism does not necessitate new gene expression or protein synthesis and is thought to be responsible for the E 2 activation of protein kinase C (PKC) [9] .
One of the key candidates for the membrane-mediated action of E 2 is a novel ERα variant, with a molecular mass of ∼36 kDa (ERα36). It differs from the classical ERα66 by lacking both transcriptional activation domains (AF1/AF2), but retains the DNA-binding domain as well as partial dimerization and an intact ligand-binding domain [10, 11] . It also contains a novel C-terminal exon that encodes 27 amino acids of unknown function. We have previously shown that this alternative ER resides in the plasma membranes of breast cancer cells and mediates E 2 's proliferative and antiapoptotic effects [12] .
Epidemiological studies have implied that sex hormones may be involved in the tumorigenesis of laryngeal carcinomas, due to the vast differences in gender susceptibility, with a male/female ratio of 11:1 [13] . The larynx is a secondary sex organ, which undergoes trophic changes in response to hormonal changes during puberty, and morphostructural changes during adulthood. Nonetheless, while other tumors of secondary sex organs have been accepted as hormone dependent cancers, laryngeal carcinoma is still a subject of controversy, and as such, its treatment is not oriented to counteract the hormonal effect.
The presence of classical cytosolic ERs is controversial in laryngeal cancer [14, 15] . Despite this, laryngeal cancer cells display E 2 responsiveness, as E 2 was found to increase proliferation of laryngeal cancer cells [16] , and a non-genomic mechanism was implicated [17] . Furthermore, the effects of E 2 were inhibited by tamoxifen [18] . These findings advocate a role for E 2 in the tumorigenesis of laryngeal cancer and warrants further exploration of its effects.
In order to further improve the understanding of the role of E 2 in the tumorigenesis and metastasis of laryngeal cancer, we examined the underlying mechanism of E 2 's effect in vitro using laryngeal cancer cell lines as the model. We hypothesized that the effect exerted by E 2 on laryngeal cancer is similar to that found in breast cancer and that ERα36-associated E 2 membrane signaling mediated by PKC is involved in promoting proliferation, protecting against apoptosis, and stimulating gene expression resulting in enhanced aggressiveness and metastasis of laryngeal cancer. In addition, we used immunohistochemistry to assess expression of ERα36 and vascular endothelial growth factor (VEGF) in histological samples from human laryngeal tumors in order to help clarify the role of E 2 in vivo.
Materials and Methods
Reagents The Hep2 laryngeal carcinoma, TT thyroid carcinoma, HeLa cervical carcinoma, and HCC38 breast cancer cell lines were validated and obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA). Minimum essential medium (MEM) and Roswell Park Memorial Institute (RPMI) 1640, both lacking phenol red, were purchased from Invitrogen (Grand Island, NY, USA), and F12K nutrient mixture was purchased from Cellgro (Manassas, VA, USA). Charcoal/dextran-filtered fetal bovine serum (FBS) was purchased from Gemini Bio-Products (Sacramento, CA, USA). The estradiol enantiomer ent-17β-estradiol (Ent-E 2 ) was kindly provided as a gift from Douglas Covey (Washington University, St. Louis, MO, USA) [19] . E 2 , E 2 conjugated to bovine serum albumin (E 2 -BSA), and taxol were purchased from Sigma (St. Louis, MO, USA). The phospholipase D (PLD) inhibitor wortmannin was purchased from EMD chemicals (Billerica, MA, USA). Protein content of samples was measured using the Macro BCA reagent kit from Pierce/Thermo Scientific (Rockford, IL, USA). ERα36 antibodies were purchased from Cell Applications Inc. (San Diego, CA, USA), GAPDH antibodies were purchased from EMD-Millipore (Billerica, MA, USA), and caveolin-1 antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). VEGF antibodies were purchased from Abcam (Cambridge, MA, USA). Details on the use of the antibodies in this study can be seen in Supplemental Table 1 . The PKC assay kit was purchased from GE Lifesciences (Pittsburgh, PA, USA). The Amplex Red phospholipase D assay kit was purchased from Life Technologies (Grand Island, NY, USA). The Titertacs TUNEL assay kit was purchased from R&D Systems (Minneapolis, MN, USA). The CaspAce assay kit was purchased from Promega (Madison, WI, USA). All primers were purchased from Eurofins (Huntsville, AL, USA). The IRB-approved larynx tissue microarray was purchased from Imgenex (San Diego, CA, USA).
Cell Culture Hep2 and HeLa cells were cultured in MEMbased media, as specified by the ATCC, containing 10 % charcoal/dextran-filtered FBS and lacking phenol red, which can mimic the effects of E 2 at low levels. HCC38 cells were maintained in RPMI 1640-based media, while TT cells were cultured in F12K media.
Presence of ER Isoforms
In order to determine whether laryngeal cancer cells express ERα36, sequence-specific primers, designed in our lab previously [12] , were used to selectively identify the traditional ERα66 and the alternatively spliced variant ERα36, as well as the G-protein coupled estrogen receptor, GPR30. RNA was extracted from Hep2, HeLa, HCC38, and TT thyroid medullary carcinoma cell lines cells using the TRIzol method. Reverse transcription was performed to produce cDNA for ERs from the laryngeal cell line. PCR was then performed to determine whether mRNAs for the receptors were expressed. Primer sequences for all mRNAs examined in this study can be seen in Supplemental Table 2 . In addition, cell lysates were fractionated according to the method previously described by Smart et al. [20] to obtain whole cell lysates, crude nuclear fractions, and plasma membrane fractions. Western blots were then used to identify the subcellular localization of ERα36 in the cell lines.
PKC and PLD Activity Subconfluent cultures of Hep2 cells were treated with E 2 , Ent-E 2 , and E 2 -BSA at the indicated time points and at a concentration of 10 −8 M unless otherwise specified. Ent-E 2 was used in order to determine if E 2 response relies on a stereospecific receptor response. The use of E 2 -BSA, which cannot pass through the plasma membrane and reach the nuclear receptor [21] [22] [23] , enables confirmation that the effects elicited by E 2 are membrane mediated. The concentration of E 2 in E 2 -BSA was calculated as follows: the E 2 -BSA provided has a molar ratio of 30 mol of E 2 to 1 mol of BSA. Based on this, using a molecular weight for E 2 equal to 272.4 g/mol and a molecular weight of BSA equal to 66,463 g/mol, we calculated a mass percentage of E 2 in a given mass of E 2 -BSA conjugate equal to 10.95 %. Using this percentage, we created a stock concentration of E 2 -BSA containing 10 −3 mol of E 2 per liter of vehicle, in this case ethanol. We then passed the solution through a centrifugal filtration unit with a molecular weight cutoff of 50kDa, allowing all free E 2 to pass through the filter and allowing us to recover a solution from the filter theoretically containing only pure conjugated E 2 -BSA. From this stock concentration, we created the dilutions used in the study.
The PLD inhibitor, wortmannin, was used at a concentration of 10 −5 M. ERα36 antibodies were used to block the effect of E 2 , in order to determine the role of ERα36 in the E 2 activation of PKC and PLD. Wortmannin and ERα36 antibodies were used 15 min prior to E 2 treatment. Cells were washed twice with phosphate buffered saline and lysed in RIPA buffer at time of harvest. PKC activity was measured using the Biotrak PKC assay kit from GE Lifesciences. PLD activity was measured using the Amplex Red PLD assay from Life Technologies and normalized using the PicoGreen DNA quantification assay. ERα36 antibodies were used to block the effect of E 2 , in order to determine the role of ERα36 in the E 2 activation of the PLD signal cascade.
Cell Proliferation, Viability, and Apoptosis In order to establish whether signaling via ERα36 can protect against apoptosis, the Hep2 cell line was treated with taxol, a known chemotherapeutic agent that induces cell death, as previously demonstrated in breast cell lines [12] . Subconfluent cultures were pretreated with E 2 for 90 min followed by taxol treatment for 4 h, after which cells were assayed for caspase-3 activity, using the CaspAce assay kit from Promega (Madison, WI) and DNA fragmentation via TUNEL. Furthermore, cell proliferation was assessed as a function of DNA synthesis, using the Click-iT EdU assay from Invitrogen (Grand Island, NY). ERα36 antibodies were used to block the effect of E 2 , thus verifying the role of ERα36 in the E 2 signal cascade.
Expression of Angiogenic and Metastatic Factors
Quantitative RT-PCR was used to determine the effect of E 2 on expression of VEGF and fibroblast growth factor 2 (FGF2), which have been implicated in pathological angiogenesis associated with tumors [24] [25] [26] . Snail1 and e-cadherin (CDH1), which are metastatic factors leading to epithelial to mesenchymal transitions [27] and the metastatic factor CXC chemokine receptor type 4 (CXCR4) [28] , were also measured in the Hep2 cell line. RT-PCR was performed with Applied Biosystems Fast SYBR Mastermix in the Applied Biosystems StepOne realtime system.
Immunohistochemistry A laryngeal cancer tissue microarray containing 39 histological slices of laryngeal cancer tissue was obtained from Imgenex Corp. Clinical information for the 39 patients with laryngeal carcinoma is presented in Table 1 . Prior to immunohistochemistry, slides were placed in a 60°C oven for 30 min, deparaffinized, and rehydrated, and antigen presentation A total of 39 laryngeal cancer subject tissues were examined by immunohistochemistry and blindly scored by three independent observers. The characteristics in the table above describe the age, sex, tissue type, TNM classification, and staging characteristics for these 39 subjects was achieved by heating in a pressure cooker for 3 min in 0.1 M sodium citrate buffer. ERα36 and VEGF presence was examined by immunohistochemistry using the LSAB immunohistological staining kit from Santa Cruz Biotechnology. Slides were counterstained with hematoxylin. A negative control for antibody detection can be seen in Supplemental Fig. 1 .
Imaging and Scoring Slides were imaged using a Leica DMLB microscope system with a 63× objective oil immersion lens. Images were taken with ImagePro for all samples and blindly scored by three independent observers according to the scoring method listed in Table 2 . ERα36 presence in all tissues was scored according to two classifications as follows: ERα36 number describes the number of cells in the tissue that are positive for ERα36; ERα36 intensity describes the intensity of the staining, which describes cells that express either low amounts of ERα36 or high amounts of ERα36. VEGF was scored in a similar manner to ERα36 for VEGF number and VEGF intensity.
Statistical Analyses For all in vitro experiments, data are represented as the mean and standard error among six individual samples. Statistical analyses were performed by analysis of variance with Bonferroni's correction for Student's t test at a significance level of α≤0.05. Histological samples were scored blindly by three independent observers, and correlations of ERα36 number and intensity to clinicopathological variables were performed using Fisher's exact test.
Results
RT-PCR results showed that Hep2 laryngeal carcinoma epithelial cells expressed the alternative splicing variant to the traditional ERα, ERα36 (Fig. 1a) . The cells also expressed mRNA for the classical ERα66, as well as the nonclassical G- 
All samples were scored blindly by three independent observers. Scores were then compared and for samples that were not scored the same by all three observers, the two most common scores were used. If no scores matched, a fourth observer blindly determined the score ER estrogen receptor and VEGF vascular endothelial growth factor protein coupled estrogen receptor GPR30 (Fig. 1a) . The presence of ERα36 protein was confirmed by Western blot analysis, which demonstrated that Hep2 cells contained protein for ERα36. While ERα36 was also identified in the TT thyroid cancer cell line, it was more pronounced in the Hep2 laryngeal cells (Fig. 1b) . Plasma membrane isolation of Hep2 cells and Western blot analysis showed that ERα36 was present in Hep2 plasma membranes along with caveolin-1, a protein found in the caveolae, which are specifically invaginated compartments of the plasma membrane that are known to house many integral membrane receptors (Fig. 1c) ; however, TT cells did not appear to have detectable levels of plasma membrane-associated ERα36, although caveolin-1 was found in this fraction (Fig. 1d) . HCC38 breast cancer cells and HeLa cervical cancer cells were used as positive controls for ERα36 present in the plasma membrane (Fig. 1c, d ). This is in agreement with our previous results, which placed this receptor in the plasma membrane of different cell lines [19] . E 2 caused a significant increase in PKC activity after 30 min of treatment (Fig. 2a) . The effect of E 2 was biphasic, with a significant increase in PKC at 10 −9 and 10 −8 M but with no effect at 10 −7 M E 2 ( Fig. 2b ). E 2 's effect was abolished with the specific PLD inhibitor wortmannin (Fig. 2c) or by antibodies specifically against ERα36 (Fig. 2d) . Furthermore, E 2 stimulated PLD activity. This effect appeared after 60 min (Fig. 3a) , between the concentrations 5×10 −9 -10 −8 M E 2 (Fig. 3b) . The enantiomer of E 2 (Ent-E 2 ) had no effect on PLD activity (Fig. 3c ). In addition, E 2 -BSA had a stimulatory effect at a concentration of 10 −9 M on PLD activity in the Hep2 cells (Fig. 3d) . Using antibodies specifically against ERα36 to block the receptor prior to E 2 treatment abolished the effect of E 2 on PLD activity (Fig. 3e) . In order to determine the physiological effects of E 2 signaling mediated by ERα36, we further examined cell survivability and downstream gene expression related to angiogenesis and metastasis. Initially, taxol was used to induce apoptosis, in order to assess the antiapoptotic effects of E 2 in cancer cells. The TUNEL assay, which measures DNA nicks associated with apoptosis, showed that taxol enhanced TUNEL, while pretreatment with 10 −8 and 10 −7 M E 2 prevented this effect (Fig. 4a) . While taxol additionally enhanced caspase-3 activity, an enzyme that plays a major role in apoptosis, 10 −8 M E 2 also blocked this effect (Fig. 4b ). E 2 also exhibited a proliferative effect in Hep2 cells, as evident from the enhanced DNA synthesis (Fig. 4c) . Pretreatment of Hep2 cells with ERα36 antibodies (1:500 dilution) blocked these antiapoptotic and proliferative effects of E 2 ( Fig. 4b, c) .
Quantitative RT-PCR analysis showed that 10
increased mRNA levels of the angiogenic factors VEGF (Fig. 5a ) and FGF2 (Fig. 5b) , while ERα36 antibodies (1:500 dilution) blocked this effect. E 2 enhanced the metastatic factor Snail1 (Fig. 5c) , while downregulating the (Fig. 2c, d , respectively). *p <0.05 versus corresponding control; #p <0.05 compared to 10
expression of e-cadherin (CDH1) (Fig. 5d) , and both of these effects by E 2 were blocked by ERα36 antibodies. Furthermore, the migratory factor CXCR4 (Fig. 5e) showed a similar enhancement with E 2 treatment, and this was again blocked with ERα36 antibodies. mRNA levels were all normalized to GAPDH (Fig. 5) . The blinded analysis of laryngeal cancer immunohistochemical staining for ERα36 demonstrated that all laryngeal cancer patient tissues were positive for the presence of the ERα36. There was a variance in the distribution of the receptor and in the degree of positive staining for the receptor. Tissues containing less ERα36 also appeared to contain less VEGF, and vice versa (Fig. 6) . Samples with relatively low ERα36 appeared to also contain less VEGF (Fig. 6a) . Conversely, samples that exhibited strong punctate staining of ERα36 also had punctate staining of VEGF, which appeared to occur around blood vessels (Fig. 6b) . While some samples with relatively high, ERα36 exhibited moderate amounts of VEGF (Fig. 6c) , others appeared to stain strongly for VEGF (Fig. 6d) . Amongst the study sample, all samples exhibited positive staining for ERα36 and VEGF, and a correlation was found between the number of ERα36 receptors and the number of VEGF (p =0.0178) ( Table 3 ). ERα36 number and intensity was further found to correlate with metastasis to regional lymph nodes (p =0.0263 and p = 0.0119, respectively). However, we did not observe a correlation between ERα36 number and intensity with other variables such as age, tumor size, or VEGF intensity (Table 3) . Discussion E 2 has been studied in multiple ER expressing cells as a potential factor that influences tumorigenesis. In breast cancer, the prototype of ER expressing cancer cells, ER-negative tumors have been found to respond to E 2 with increases in PKC activity, which correlates with enhanced tumorigenicity [12] . The discovery of a novel ER variant, ERα36, opened the possibility that cancers previously labeled as non-hormone dependent and ER negative might in fact be susceptible to the effects of E 2 via this membrane receptor, as was demonstrated in ER negative breast cancers [9, 12] . In breast cancer, ERα36 was found to be a key cellular and transcriptional regulator of proliferation and enhanced aggressiveness [11, 12] , thus emphasizing the importance of characterizing further Fig. 3 Estradiol effects on PLD activity in Hep2 laryngeal carcinoma cells. A time-course evaluation of PLD activity in response to 10 −8 M E 2 treatment of Hep2 cells shows that PLD activity is enhanced 60 min after treatment (a), while a biphasic effect is observed in response to different doses (b). When the enantiomer for E 2 , Ent-E 2 , is used to treat Hep2 cells, no increase in PLD activity is observed (c). When E 2 -BSA is used to treat Hep2 cells, an increase in PLD activity is only observed with 10 −9 M E 2 -BSA (d). When Hep2 cells were pretreated with antibody against ERα36, the effect of E 2 on PLD activity was abolished (e). *p <0.05 versus corresponding control; #p <0.05 compared to E 2 only its presence and role in other cancers that are subject to the influences of sex hormones.
Previous work has suggested that laryngeal squamous cell carcinomas exhibit sex hormone-dependent behavior [15] . Here, we show that laryngeal carcinoma cell lines possess functional ERα36, and it is present in the plasma membranes. The existence of ERα36 in the plasma membrane was not uniform in all cancer cells, however, as demonstrated by the lack of ERα36 in TT thyroid cancer cells.
Previous studies in breast cancer demonstrated that ERα36 is localized specifically in the caveolae and is responsible for the E 2 activation of the PKC signaling cascade [12] . This was also the case for Hep2 cells; ERα36 was localized with caveolin-1, indicating its present in caveolae. Moreover, E 2 stimulated PKC activity in Hep2 cells via a mechanism comparable to that seen in the breast cancer cells. E 2 caused an increase in PKC activity that was dependent on PLD, based on its inhibition by wortmannin. E 2 activated PLD via a receptormediated mechanism; the enantiomer of E 2 had no effect, and antibodies to ERα36 blocked E 2 -dependent increases in PLD activity. It was also membrane-dependent as E 2 -BSA was able to elicit the response. GPR30, which is a well-studied alternative receptor for estrogen, was also expressed in Hep2 cells. Previously, we demonstrated that antibodies against GPR30 did not block the effect of E 2 nor E 2 -BSA [12] , indicating that GPR30 does not mediate the membrane-associated responses to E 2 examined in the present study. Furthermore, blocking ERα36 signaling with antibodies abolished the protective and proliferative effects of E 2 , indicating that ERα36 has a role in tumorigenesis of laryngeal cancer and in the antiapoptotic effect of E 2 against chemotherapeutics.
PKC has a key role in promoting tumorigenesis [29] . Higher PKC activity correlates in vivo to enhanced tumor aggressiveness and progression [12, 29, 30] , while in vitro, activation of the PKC signaling pathway enhances cell proliferation and survival via an antiapoptotic mechanism [9, 12] . Activation of PKC initiates a signaling cascade that results in activation of the ERK1/2 family of mitogen-activated protein kinases, providing an alternative method for steroid hormones to modulate gene expression rather than by traditional nuclear receptor-mediated pathways [12] .
PKC expression in laryngeal cancer was reported to be significantly higher than that found in normal laryngeal epithelium and adjacent noncancerous laryngeal epithelium and was correlated with clinical stage and cervical lymph node metastasis [31] . In our study, in response to E 2 , Hep2 cells demonstrated an increase in PKC activity followed by an upregulation of angiogenic and metastatic factors. Clinical analysis of patients with laryngeal cancer revealed an association between the number and concentration of ERα36 and metastasis to regional lymph nodes. A similar relationship was observed in other cancer cells, such as breast [12] and gastric carcinoma [32] . Previous studies found that E 2 activation of PKC mediates the expression of several metastatic factors [33] , thus promoting tumor metastasis [12] . Tamoxifen was found to exert its effect, among others, by inhibiting the PKC signal pathway [9, 34] , thus opening the possibility that tamoxifen may be considered in the treatment of laryngeal cancer.
There are a number of alternative mechanisms by which PKC is activated and regulated via a membrane receptor, of which phospholipase A2, phospholipase C, and phospholipase D have a prominent role. The mechanism by which this family of phospholipases cleaves different membrane phospholipids, such as phosphatidylcholine or phosphatidylinositol, to form diacylglycerol, thus activating PKC is well studied [35] . However, there is increasing evidence that this mechanism is not one directional, as in the case of PLD, in which PKC was found to be an upstream regulator of PLD [31] . Moreover, PLD in itself has antiapoptotic effects, through the production of lysophosphatidic acid, which in turn leads to decreased caspase-3 activity [35] . Our findings support that in laryngeal cancer, E 2 exerts its effects through the PLD-PKC pathway. Further research is needed in order to elucidate the mechanism by which this pathway renders laryngeal cancer cells sensitive to the effects of E 2 .
These effects can explain the ability of E 2 to enhance tumor aggressiveness directly by allowing cells to proliferate and evade the effects of common chemotherapeutics. Not only can these cells proliferate and evade apoptosis in the presence of E 2 , but E 2 may also lead to a more aggressive cancer by leading the primary tumor and metastasizing to other secondary sites in the patient. As tumors grow, cells within the tumor secrete VEGF, leading to vascularization of the tumor and providing a network through which these tumor cells can enter the vasculature and travel throughout the body. Our previous results showed that E 2 enhanced VEGF and FGF expression in vitro, and the in vivo correlation between ERα36 and VEGF suggest that patients with high levels of ERα36 may have a more aggressive tumor phenotype as evidenced by the correlation to lymph node metastasis. These patients may benefit from treatments such as tamoxifen, which can block signaling of E 2 through ERα36, regardless of whether they contain traditional ERs.
As opposed to breast cancer in which the role of E 2 signaling has been studied mainly in female patients, in this study, we observed that E 2 plays also a major role in development of cancer in male patients. Our findings suggest that male patients with laryngeal cancer, and possibly other cancers that are hormone dependent, may benefit from ER-targeting treatments. Originally, we sought to determine if the role of ERα36 in laryngeal cancer is sex dependent, but were unable to do so due to the low frequency of laryngeal cancer in women, and thus our sample of tissues contained samples from mostly male patients.
The findings of this study present compelling evidence that laryngeal cancer is hormone responsive, specifically to the effects of E 2 , via ERα36. This membrane receptor activates several pathways, which were found both in vitro and in vivo, to correlate with laryngeal cancer progression and aggressiveness. E 2 also elicits antiapoptotic effects that can oppose the effects of chemotherapeutic agents, such as taxol, and might, thus, confer resistance to treatment. Further investigation is warranted in order to elucidate the role of E 2 and this membrane-mediated mechanism and to shed light on its impact on the treatment and management of laryngeal cancer clinically.
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